SILO PHARMA INC (SILO) Stock Price, Quote, News and Overview
NASDAQ:SILO - Nasdaq - US82711P2011 - Common Stock - Currency: USD
SILO Quote, Performance and Key Statistics
1.31
+0.04 (+3.15%)
The current stock price of SILO is 1.31 USD. In the past month the price decreased by -23.84%. In the past year, price decreased by -18.12%.
SILO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.83 | 372.42B | ||
| AMGN | AMGEN INC | 16.04 | 170.67B | ||
| GILD | GILEAD SCIENCES INC | 25.17 | 144.59B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1674.9 | 124.78B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.3 | 76.35B | ||
| ARGX | ARGENX SE - ADR | 238.59 | 37.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.00B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.42B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.57B | ||
| BIIB | BIOGEN INC | 8.95 | 21.47B | ||
| NTRA | NATERA INC | N/A | 18.68B | ||
| GMAB | GENMAB A/S -SP ADR | 24.96 | 15.06B |
Related stock screener links
About SILO
Company Profile
Silo Pharma, Inc. is a developmental stage biopharmaceutical company, which engages in the merging of traditional therapeutics with psychedelic research. The company is headquartered in Sarasota, Florida and currently employs 3 full-time employees. The company went IPO on 2012-01-05. The firm is focused on developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. The company is engaged in acquiring and/or developing intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological disorders. The Company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. Its SP-26 is a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. Its two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS).
Company Info
SILO PHARMA INC
677 N. Washington Blvd
Sarasota FLORIDA US
Employees: 3
Company Website: https://silopharma.com/
Investor Relations: http://ir.silopharma.com
Phone: 17184009031
SILO PHARMA INC / SILO FAQ
What is the stock price of SILO PHARMA INC today?
The current stock price of SILO is 1.31 USD. The price increased by 3.15% in the last trading session.
What is the ticker symbol for SILO PHARMA INC stock?
The exchange symbol of SILO PHARMA INC is SILO and it is listed on the Nasdaq exchange.
On which exchange is SILO stock listed?
SILO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SILO PHARMA INC stock?
7 analysts have analysed SILO and the average price target is 10.2 USD. This implies a price increase of 678.63% is expected in the next year compared to the current price of 1.31. Check the SILO PHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SILO PHARMA INC worth?
SILO PHARMA INC (SILO) has a market capitalization of 5.87M USD. This makes SILO a Nano Cap stock.
How many employees does SILO PHARMA INC have?
SILO PHARMA INC (SILO) currently has 3 employees.
What are the support and resistance levels for SILO PHARMA INC (SILO) stock?
SILO PHARMA INC (SILO) has a support level at 1.25 and a resistance level at 1.84. Check the full technical report for a detailed analysis of SILO support and resistance levels.
Should I buy SILO PHARMA INC (SILO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SILO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SILO, evaluating the profitability, health, valuation and growth aspects
- SILO PHARMA INC (SILO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SILO PHARMA INC (SILO) Sales and EPS estimates to see what analysts future expectations are.
- SILO PHARMA INC (SILO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SILO PHARMA INC (SILO) Insider and Institutional Ownership to learn about the owners and their transactions.
- SILO PHARMA INC (SILO) Stock Chart to make your own analysis
- SILO PHARMA INC (SILO) Latest news and press-releases to stay up to date.
Does SILO PHARMA INC (SILO) stock pay dividends?
SILO does not pay a dividend.
When does SILO PHARMA INC (SILO) report earnings?
SILO PHARMA INC (SILO) will report earnings on 2025-03-24, after the market close.
What is the Price/Earnings (PE) ratio of SILO PHARMA INC (SILO)?
SILO PHARMA INC (SILO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.18).
What is the Short Interest ratio of SILO PHARMA INC (SILO) stock?
The outstanding short interest for SILO PHARMA INC (SILO) is 3.63% of its float. Check the ownership tab for more information on the SILO short interest.
SILO Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to SILO. When comparing the yearly performance of all stocks, SILO is one of the better performing stocks in the market, outperforming 85.71% of all stocks.
SILO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SILO. While SILO has a great health rating, there are worries on its profitability.
SILO Financial Highlights
Over the last trailing twelve months SILO reported a non-GAAP Earnings per Share(EPS) of -1.18. The EPS increased by 11.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -44.17% | ||
| ROE | -55.78% | ||
| Debt/Equity | 0 |
SILO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to SILO. The Buy consensus is the average rating of analysts ratings from 7 analysts.